MM-398 is an investigational nanotherapeutic consisting of the chemotherapeutic irinotecan, encapsulated in a liposomal sphere. 

In line with Merrimack’s mission to create integrated medicines, we are developing an imaging diagnostic and using our Network Biology approach to simultaneously develop biopsy-based assays, both of which are designed to help identify patients most likely to respond to MM-398 treatment. Our goal is to enable MM-398 to provide a more robust and durable clinical response than observed with conventional chemotherapy.

Our research suggests an opportunity to develop MM-398 in multiple indications. 

MM-398 in Clinical Trials

MM-398 is being evaluated in clinical trials for its ability to treat tumors resistant to chemotherapy across multiple types of cancers, including pancreatic, lung, colorectal and glioma. The FDA and the European Medicines Agency granted MM-398 orphan drug designation in 2011 in metastatic pancreatic cancer.

CLICK HERE to learn more about MM-398 in the Clinic

For healthcare providers seeking information about Merrimack’s support for the single-patient expanded access program (EAP) for MM-398 (irinotecan liposome injection), please contact Idis, the EAP program administrator:

EAP Contact:
Only physicians can enroll patients in an EAP. Patients should work through their physician to determine eligibility.